The Journey for Lung Cancer Screening where we Stand Today

Area of Science:

• Oncology
• Radiology
• Public Health

Background:

• Lung cancer is a major global cause of cancer death.
• Many patients are diagnosed with advanced lung cancer, limiting treatment options.
• Early detection is crucial for improving patient outcomes.

Purpose of the Study:

• To review the evidence for lung cancer screening using low-dose computed tomography (LDCT).
• To analyze key lung cancer screening trials, including the National Lung Screening Trial (NLST), Early Lung Cancer Action Program (ELCAP), and the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial.
• To discuss lung cancer risk prediction models, cost-effectiveness of LDCT screening, and recent guideline updates.

Main Methods:

• Literature review of major lung cancer screening trials (NLST, ELCAP, NELSON).
• Analysis of lung cancer risk prediction models for identifying high-risk populations.
• Evaluation of the cost-effectiveness of LDCT screening in various smoker demographics.
• Review of current lung cancer screening guidelines and recent changes.

Main Results:

• Low-dose computed tomography (LDCT) has demonstrated a significant reduction in lung cancer mortality.
• Evidence supports LDCT screening for specific groups of current and former smokers.
• Risk prediction models and cost-effectiveness analyses provide valuable insights for targeted screening programs.

Conclusions:

• LDCT screening is an effective tool for reducing lung cancer mortality in high-risk individuals.
• LDCT facilitates the early diagnosis of lung cancer, improving treatment efficacy.
• Updated guidelines reflect the growing evidence supporting LDCT lung cancer screening.